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Plasmodium malariae is the only human malaria parasite 
species with a 72-hour intraerythrocytic cycle and the abil-
ity to persist in the host for life. We present a case of a P. 
malariae infection with clinical recrudescence after directly 
observed administration of artemether/lumefantrine. By us-
ing whole-genome sequencing, we show that the initial in-
fection was polyclonal and the recrudescent isolate was a 
single clone present at low density in the initial infection. 
Haplotypic analysis of the clones in the initial infection re-
vealed that they were all closely related and were presum-
ably recombinant progeny originating from the same infec-
tive mosquito bite. We review possible explanations for the 
P. malariae treatment failure and conclude that a 3-day arte-
mether/lumefantrine regimen is suboptimal for this species 
because of its long asexual life cycle.
During the past decade, intensification of malaria con-trol efforts has substantially reduced the global bur-
den of malaria from Plasmodium falciparum. This trend 
has often been associated with increased recognition of the 
burden of malarial disease caused by the other Plasmodium 
species (1). P. malariae, 1 of the 6 Plasmodium species that 
commonly infect humans, is endemic throughout parts of 
Africa (2,3), South America (4), Asia, and the western Pa-
cific (5). P. malariae is unique among the human-infective 
Plasmodium species in having a 72-hour intraerythrocytic 
life cycle with variable but often prolonged pre-erythrocyt-
ic intrahepatic development (6). P. malariae can persist in 
the human host for years and possibly an entire lifetime. 
Although it is often asymptomatic, chronic parasitemia in 
endemic areas is associated with substantial rates of illness, 
including anemia and nephrotic syndrome (7–9).
A key strategy for malaria elimination is strengthen-
ing of health systems to deliver early diagnosis and highly 
effective therapy. Artemisinin-based combination therapy 
(ACT) has been central to this approach, with proven effi-
cacy against multidrug-resistant P. falciparum, multidrug-
resistant P. vivax, and P. knowlesi (10–13). In recent years, 
there have been increasing calls for a universal policy of 
ACT for all species of malaria (10–13). However, the ef-
ficacy of ACT against P. malariae is poorly documented.
Although chronic infection with P. malariae is well-
recognized (14), little is known regarding how the parasites 
manage to evade host immunity and the intrahost dynamics 
of the underlying parasite population. Recent advances in 
molecular genetics have produced the first descriptive anal-
yses of the whole genome sequence of P. malariae (15,16). 
The P. malariae reference genome is 33.6 Mb in size, has 
6,540 genes, and has an average guanine plus cytosine con-
tent of 24% (15).
We report a case of a P. malariae infection in a pa-
tient residing in a non–malaria-endemic environment that 
resulted in recrudescence months after treatment with arte-
mether/lumefantrine (AL). By using whole-genome se-
quencing of isolates from the initial and the recrudescent 
infections, we show that the 2 major P. malariae haplo-
types, constituting ≈90% of the parasite load in the initial 
infection, were cleared successfully by AL, whereas a third 
haplotype, constituting a minority subpopulation in the ini-
tial infection, survived and recrudesced.
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Results
The Patient
A 31-year-old Uganda-born man, weighing ≈77 kg (≈170 
lbs), who had been a resident in Australia for 5 years 
sought care at Royal Darwin Hospital (Darwin, Northern 
Territory, Australia) on March 1, 2015, with a 4-day his-
tory of fevers and headaches. He had returned to Australia 
56 days previously after a 2-week trip to Uganda visit-
ing friends and relatives (Figure 1, panels A, E). He had 
spent 14 days in a rural malaria-endemic area in eastern 
Uganda. Although he had not taken regular malaria pro-
phylaxis, he had self-medicated with a locally acquired 
oral course of AL on the second and third days of his trip, 
despite being clinically well (Figure 1, panels B, D). He 
returned to Australia (now a malaria-free country) in Jan-
uary 2015 until seeking care after a short febrile illness in 
late February. On examination, he had a tympanic tem-
perature of 37.5°C and a heart rate of 110 beats/min but no 
manifestations of severe malaria. Rapid diagnostic testing 
with BinaxNOW (Binax, Inc. Inverness Medical Profes-
sional Diagnostics, Scarborough, ME, USA) for malaria 
was positive for aldolase but negative for histidine-rich 
protein 2. Species-specific PCR was positive for P. ma-
lariae and negative for all other Plasmodium species (on-
line Technical Appendix, https://wwwnc.cdc.gov/EID/ar-
ticle/23/8/16-1582- Techapp1.pdf). Thick and thin blood 
film examination confirmed P. malariae parasitemia 
(12,140 parasites/µL) with all stages of asexual develop-
ment visible on the blood film (online Technical Appen-
dix Figure 1, panels A, B). The blood film was otherwise 
unremarkable; in particular, no evidence for hyposplen-
ism was found. The patient was not immunosuppressed, 
and an HIV serologic test was negative. A hepatitis C 
Figure 1. Timeline of the clinical 
case of a patient with Plasmodium 
malariae infection diagnosed 
and treated at Royal Darwin 
Hospital, Darwin, Northern 
Territory, Australia, March–
April 2015, showing the timing 
(A), treatment (B), parasite’s 
genotype as inferred from whole-
genome sequencing (C), clinical 
presentation (D), and location 
(E). The rounded arrow indicates 
the recrudescence of the minor 
haplotype 2 in the initial infection 
to dominate monoclonally in the 
second infection. AL, artemether/
lumefantrine; H1, haplotype 1; H2; 
haplotype 2; MP Ag, pan-malarial 
antigen; R1, reference haplotype.
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serologic test was positive but with a viral load that was 
below the limit of quantification (<12 IU/mL).
The patient was administered a single 20/120 mg tablet 
of AL on the first day because of a prescribing error but 
subsequently continued with a supervised standard regi-
men of 80/480 mg every 12 hours taken with fatty food to 
complete a full course of 6 doses over 3 days, equivalent 
to a total dosage of 6.2 mg/kg of artemether and 37.4 mg/
kg of lumefantrine. Glucose 6-phosphate dehydrogenase 
function was normal, and a single 30-mg dose of prima-
quine was administered on day 2. His hemoglobin was 126 
g/dL and he received no blood transfusion. After treatment, 
his parasitemia declined to 1,269/µL at 32 hours, 488/µL 
at 41 hours, and 55/µL at 56 hours. He was afebrile and 
symptom-free within 36 hours of admission. However, be-
fore discharge on day 6, thick blood film examination was 
still positive (192/µL), but by day 11, his repeat blood film 
examination and his aldolase rapid diagnostic test results 
were negative.
The patient remained in urban Darwin but returned to 
the hospital 52 days later, on April 22, 2015, with a 2-week 
history of fevers, fatigue, and headache. Microscopy again 
identified P. malariae with a parasite count of 3,332/µL 
(online Technical Appendix Figure 1, panels C, D). Chlo-
roquine was unavailable, so the patient was re-treated with 
oral hydroxychloroquine with an 800-mg loading dose, fol-
lowed by 400 mg at 6 hours, 400 mg at 24 hours, 400 mg 
at 48 hours, and a single 45-mg dose of oral primaquine. 
The parasite count declined rapidly to 37/µL at 28 hours, 
191/µL at 49 hours, and 76/µL at 88 hours of treatment. 
His symptoms resolved rapidly. Thick and thin blood films 
were negative on day 4 and remained negative on retest-
ing at days 8, 35, 41, and 84, and the patient remained free 
of symptoms throughout. A PCR on blood collected at 12 
weeks was also negative.
Whole-Genome Sequencing
Extensive sequencing was performed from blood sam-
ples obtained from the initial (PmUG01) and recrudes-
cent (PmUG02) infection (online Technical Appendix 
Table 1), covering >99% of the genome at >20× for 
both infections. By using additional P. malariae sam-
ples published previously (15), we identified single-
nucleotide polymorphisms (SNPs) using GATK’s Uni-
fiedGenotyper (Broad Institute, Cambridge, MA, USA) 
(17) and filtered them based on several parameters (on-
line Technical Appendix Table 2). A multidimensional 
scaling plot of the samples based on their SNP allele 
frequency-spectra revealed that PmUG01 and PmUG02 
were more closely related to each other than to any of the 
other samples (online Technical Appendix Figure 2), as 
expected if they were related recombinants derived from 
the same original infection.
Searching solely for SNPs that distinguish PmUG01 
and PmUG02, we identified 2,631 variants after filtering 
(online Technical Appendix Table 2). PmUG01 was the 
sample from which the reference genome (R1) was con-
structed (15), and only 1 SNP in PmUG01 suggested a 
nucleotide base different from the reference strain, prob-
ably because it was in a repetitive region (online Techni-
cal Appendix Table 4). PmUG01 appeared to be a poly-
clonal infection with a bimodal distribution of alternate 
(i.e., nonreference) alleles at frequencies of 0.15 and 0.35 
(online Technical Appendix Figure 3, panel A). Converse-
ly, PmUG02 appeared to be a monoclonal infection with 
≈85% of sites being either fixed for the reference allele or 
for an alternative allele (online Technical Appendix Fig-
ure 3, panel B). Comparison of the initial and recrudescent 
infections revealed that heterozygous sites in the initial in-
fection had become either homozygous alternate (≈40%) or 
homozygous reference (≈45%) (online Technical Appendix 
Table 4). Analysis of the genotype calls across the genome 
(online Technical Appendix Figure 4) revealed that, where-
as the heterozygous sites from the initial infection were 
spread evenly across the 14 chromosomes, the homozygous 
alternate sites in the recrudescent infection were present 
in distinct clusters, implying that the initial infection was 
polyclonal and that the recrudescence was attributable to a 
single clone that was closely related to the reference clone.
Comparison of the distribution of the alternate allele 
frequencies throughout the genome of the initial and re-
crudescent strains (Figure 2) revealed bands of alleles at 
frequencies of ≈0.15 and ≈0.35 in the initial infection spa-
tially clustered throughout the genome. The alleles that 
increased in relative frequency in PmUG02 were mostly 
at frequencies of ≈0.15, whereas the alleles at frequencies 
of ≈0.35 decreased in frequency and the positions became 
homozygous reference in PmUG02 (Figure 2). These data 
strongly suggested that, in addition to R1, 2 minor clones 
(minor haplotypes) were also present. Of these 2, the clone 
with the haplotype comprising alternate alleles at frequen-
cies of ≈0.35 (H1) appeared to have been eliminated during 
the drug treatment because no alleles specific to H1 were 
present in the recrudescent infection. The other minor clone 
comprised a haplotype with alternate alleles at frequencies 
of ≈0.15 (H2) in the initial infection; this clone appeared to 
have caused the recrudescence (Figure 1, panel C). Based 
on the relative alternate allele frequencies of the 3 haplo-
types in the initial infection, ≈60% of the parasites were 
of the R1 haplotype, 30% of H1, and 10% of H2. These 
estimates were broadly consistent with the ratio of alleles 
in tri-allelic sites (0.69:0.22:0.09) (online Technical Ap-
pendix Table 5). The ratio of alleles in these tri-allelic sites 
changes markedly in PmUG02 (0.13:0.06:0.81), with over 
half of sites becoming homozygous for H2 but with some 
heterogeneity in the other sites (online Technical Appendix 
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Table 6), probably because of the low coverage depth and 
because they were in repetitive regions.
Unexpectedly, several SNPs at high allele frequen-
cies (>0.4) also increased in frequency in the recrudescent 
strain. Testing by using additional P. malariae samples (15) 
showed that ≈80% of these SNPs were homozygous for the 
alternate allele in >1 other P. malariae samples, whereas 
≈30% were homozygous in all other P. malariae samples 
(online Technical Appendix Figure 5). This observation 
indicated that of these unusual SNPs, ≈50% were highly 
polymorphic, whereas ≈30% were probably low-frequency 
SNPs with rare variants present in the reference strain. This 
would explain the observation of SNPs with high reference 
allele frequency in the initial infection that became homo-
zygous alternate in the recrudescence, given that they were 
probably SNPs with alternate alleles shared by H1 and H2.
To clarify the relationships of the different haplotypes 
with each other, we classified every genome region by 
whether any of the 3 haplotypes were identical to each other 
(Figure 2; online Technical Appendix). Approximately 25% 
of the genome is shared between H1 and R1 and between H2 
and R1. No regions were shared between H1 and H2, which 
suggested that both H1 and H2 were half-siblings of R1, al-
though they did not share any parent between themselves 
(online Technical Appendix Figure 6). The finding that all 
haplotypes were related to each other through R1 further sug-
gested that all strains were transmitted from the same mos-
quito bite and that the mosquito ingested at least 4 different 
parental haplotypes (online Technical Appendix Figure 6).
Analysis of SNPs in orthologs of known drug-resis-
tance genes identified 3 nonsynonymous SNPs in the mul-
tidrug resistance protein 2 (mdr2) gene, 1 of which was in 
the ABC transporter domain, and 2 in the ABC transporter 
domain of ABC transporter C family member 2, present in 
the recrudescent strain (H2) but not the other strains (on-
line Technical Appendix Table 7). No evidence was found 
for copy number variation in any gene compared with the 
reference strain, and the reference strain did not appear to 
Figure 2. Analysis of the minor 
haplotype (H2) that caused 
recrudescence of Plasmodium 
malariae infection in a patient at 
Royal Darwin Hospital, Darwin, 
Northern Territory, Australia, March–
April 2015, showing distribution 
of SNP alternative (nonreference) 
allele frequencies across the 14 
chromosomes (boxes in the middle 
and dotted vertical lines) in the 
initial infection (bottom plot) and 
the recrudescence (top plot). The 
SNP colors (green, increasing 
in frequency; red, decreasing in 
frequency) form 2 clear bands, 
corresponding to H1 (yellow box) and 
H2 (pink box). H2 probably caused 
the recrudescence given that all of 
its alleles increase considerably in 
frequency. Colored boxes in center of 
chart indicate chromosome sharing. 
H1, haplotype 1; H2; haplotype 2; 
R1, reference genome; SNP, single- 
nucleotide polymorphism.
have an amplification of the multidrug resistance protein 1 
gene compared with any of the other P. malariae samples.
Discussion
This report of a case of recurrent P. malariae malaria is un-
usual in that it describes the molecular characterization and 
confirmation of a treatment failure after directly observed, 
appropriately administered, quality-assured AL dosing in a 
nonendemic environment where reinfection was not pos-
sible. Whole-genome sequencing demonstrated that the 
recrudescence was attributable to a minor clone present in 
the initial polyclonal infection. The case raises 2 important 
questions: first, what was the cause of treatment failure; 
and second, why did recrudescence arise from the minor 
clone rather than a dominant reference clone?
Although the efficacy of AL for P. malariae infection 
is assumed in many national guidelines (18), P. malariae 
monoinfections are relatively unusual and often of low 
density. To our knowledge, there have been no published 
efficacy series of AL with the long follow-up necessary to 
assess efficacy against a parasite with a 72-hour life cycle. 
In a nonrandomized efficacy study of 4 PCR-confirmed P. 
malariae infections treated with AL in Gabon (1 P. malar-
iae monoinfection and 3 mixed P. malariae/P. falciparum 
infections), all 4 were microscopy negative at day 28, with 
no follow-up beyond this time (19). Among 80 PCR-con-
firmed P. malariae/P. falciparum mixed species infections 
in Uganda, 12% were still PCR-positive for P. malariae at 
day 7 and 6% were still PCR-positive on day 17 (20). An 
additional 3 reports have documented P. malariae infec-
tions occurring at 38 days, 47 days, and 4 months after AL 
treatment of an initial microscopy-diagnosed P. falciparum 
infection in returned travelers with no further possible ma-
laria exposure (21–23).
Figure 3. The different 
scenarios under which a second 
Plasmodium malariae infection 
could have occurred from the 
initial infection diagnosed in a 
patient at Royal Darwin Hospital, 
Darwin, Northern Territory, 
Australia, March–April 2015. 
Initial infection is shown in the 
inner circle. A) A completely new 
infection might have caused 
the second malaria onset. B) 
The drug might not have been 
absorbed at sufficient levels to 
kill all the parasites in the blood 
(pharmacokinetic cause). C) The 
longer intraerythrocytic life cycle 
of P. malariae (72 hours) might 
have enabled some parasites 
to survive the drug action until 
lumefantrine concentrations 
became subtherapeutic 
(pharmacokinetic cause). D) H2 
parasites might have differentially 
sequestered with a biomass out 
of proportion with the peripheral 
parasitemia. E) Some parasites 
might have formed dormant 
stages in the liver, blood, or 
elsewhere (pharmacodynamic 
cause). F) An immune response 
might have been differentially 
primed against haplotypes at 
higher biomass. G) A haplotype 
within the initial infection might 
have been relatively drug resistant 
(fitness advantage). H1,  
haplotype 1; H2, haplotype 2; R1,  
reference genome.
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Several plausible explanations might account for a re-
currence of P. malariae parasitemia after treatment with 
AL (Figure 3). The last indigenous case of malaria in the 
Northern Territory was in 1962, with no subsequent cases 
of introduced malaria or autochthonous transmission (24); 
hence, the possibility of reinfection can be excluded (Fig-
ure 3, panel A). Additionally, the presence of the H2 hap-
lotype in the initial infection and recrudescent infection 
confirms treatment failure.
Inadequate drug absorption resulting in suboptimal 
serum drug concentrations can cause treatment failure 
(Figure 3, panel B). Artemether is rapidly absorbed and 
eliminated (half-life of a few hours), whereas lumefantrine 
is variably absorbed and more slowly eliminated (half-life 
≈3.2 days) (25). Lumefantrine is a lipophilic compound 
with erratic bioavailability unless administered with a 
small fatty meal (26), and for this reason, guidelines rec-
ommend administration of AL with a fatty meal such as 
milk or a small biscuit. In the case of our patient, we were 
unable to confirm adequate serum concentrations of lume-
fantrine; however, the patient took a complete course of 
treatment, and all doses were supervised in the hospital and 
administered with a milk biscuit to ensure good absorption. 
None of the treatment doses were vomited. In this scenar-
io, one would expect >98% efficacy against P. falciparum 
(27). In addition, the clones associated with the R1 and H1 
haplotypes, accounting for ≈90% of the parasite load, were 
cleared, suggesting that the plasma drug concentrations 
were sufficient to eliminate both infections. Nevertheless, 
considerable inter-individual variation exists in lumefan-
trine exposure, and this patient may have had relatively 
low concentrations.
Cure of malaria in a nonimmune patient requires that 
antimalarial blood concentrations are sustained above the 
parasites’ MIC until the entire parasite biomass has been 
eliminated. In the presence of antimalarial drugs, the para-
site biomass generally decreases over time in an exponen-
tial manner, with drug concentrations needing to be sus-
tained above the MIC for >4 life cycles (28). In the case of 
our patient, the baseline parasitemia at initial presentation 
was 12,000/µL, which is relatively high compared with 
most P. malariae clinical infections (6). Thus, the combi-
nation of the long parasite life cycle such that 1 rather than 
2 asexual cycles were exposed to artemether, and the short 
period (≈16 days) for which lumefantrine was at concen-
trations sufficient to kill the parasite may have resulted in 
parasites surviving the initial treatment and reestablishing 
a chronic parasitemia that was then sustained for 50 days 
before recrudescing (Figure 3, panel C).
Another possibility is that some parasites could have 
sequestered (Figure 3, panel D) or become dormant (Fig-
ure 3, panel E). Whereas dormancy would allow a propor-
tion of the parasites to evade blood-stage schizontocidal 
activity, plausible sites for sequestration of P. malariae–
infected erythrocytes would still be exposed to therapeutic 
concentrations of blood-stage antimalarials, making this 
possibility an unlikely explanation for this patient’s recru-
descent infection. P. malariae is well-recognized as having 
a prolonged preerythrocytic phase and a prepatent period 
of 16–59 days (6). The initial treatment course of AL was 
administered 56 days after the patient left Uganda, so any 
preerythrocytic stages were probably not present at the 
time of initial AL treatment.
Although the ability to form hypnozoites (dormant 
exoerythrocytic stages) occurs in 3 human malaria parasite 
species (P. vivax, P. ovale curtisi, and P. o. wallikeri), the 
evidence that latent exoerythrocytic stages do not occur in 
P. malariae is limited (6). Case reports have documented 
P. malariae producing symptomatic disease many years af-
ter exposure to infection, as noted in the case of a 74-year-
old woman in Greece with P. malariae reactivation after 
>40 years (29). Such latency suggests that low-level para-
sitemia could persist for many years after infection, and 
indeed may be lifelong. In the case of our patient, para-
site recrudescence occurred >100 days after he had left a 
malaria-endemic area.
Although inadequate drug absorption (Figure 3, panel 
B), duration of treatment (Figure 3, panel C), or dormancy 
(Figure 3, panel E) all may have contributed to parasite 
recrudescence, these indiscriminate explanations would 
be expected to occur primarily in the dominant strain dur-
ing the initial infection (28) (online Technical Appendix 
Figure 7). One could speculate that the H2 minor parasite 
population might have emerged from a hepatic schizont 
that ruptured days after those giving rise to the majority 
haplotypes and, despite genetic similarity, had substantial 
differences in surface antigenicity. The antibody response 
to the primary infection, which would have reached a max-
imum ≈3 weeks after the illness began, would have been 
directed against the majority haplotypes and might not 
have recognized the minor population (Figure 3, panel F). 
Alternatively, more of the minor population might have 
been in the dormant state compared with the dominant cir-
culating clones with R1 or H1 haplotypes, or more might 
have been at a higher biomass in erythrocytes sequestered 
elsewhere, enabling a proportion to evade antimalarial 
drug action and recrudesce.
Finally, the minority clone with H2 haplotype might 
have recrudesced because of a fitness advantage over 
the other clones/haplotypes (online Technical Appen-
dix Figure 7, panels B, C), possibly including relative 
resistance to either artemether or lumefantrine (Figure 
3, panel G). In P. falciparum, resistance to artemether 
is acquired through mutations in the propeller domain 
of K13 (30), whereas P. falciparum resistance to lume-
fantrine is associated with mutations and copy number 
variation in the Pfmdr1 gene (31,32). Although neither 
of these genes had nonsynonymous mutations in H2, 1 
nonsynonymous mutation was noted in the ABC trans-
porter domain of mdr2, potentially involved in artemis-
inin resistance (33,34), and 2 nonsynonymous mutations 
were noted in the multidrug resistance–associated pro-
tein 2 gene, which has been implicated in reduced ex 
vivo susceptibility to lumefantrine in P. falciparum (35). 
We also identified 2 nonsynonymous SNPs in the dihy-
drofolate reductase homologue. Low serum concentra-
tions, a modest reduction in lumefantrine efficacy, the 
prolonged life cycle of P. malariae, and rapid elimina-
tion of lumefantrine all might have contributed to the 
observed treatment failure in our patient.
In conclusion, we have described a case of P. ma-
lariae recrudescence occurring in a non–malaria-endem-
ic country after adequately administered AL. Whole-
genome sequencing data revealed that the monoclonal 
recrudescence consisted of a minor haplotype that ac-
counted for ≈10% of the initial infection and that all the 
haplotypes in the initial infection were related to each 
other and therefore probably originated from the same 
infective mosquito bite. Although the haplotypes were 
closely related, the genomic data suggest that >4 paren-
tal haplotypes were ingested by the mosquito, indicating 
considerable diversity and transmission of P. malariae. 
This case raises concerns about the adequacy of ACTs 
with a short half-life partner drug, such as AL, in treating 
P. malariae infections and suggests that optimal ACTs 
to treat P. malariae should include a slowly eliminated 
partner drug. Our findings reinforce the importance of a 
longer duration of follow-up monitoring of patients in-
fected with P. malariae for late recrudescence.
The sequencing data generated in this study are provided 
in the European Nucleotide Archive under accession codes 
ERS1110316 and ERS1110319.
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